S100A1 and cancer: Like S100B, increased S100A4 levels is linked to poor survival in cancer patients.206–207 Therefore, developing S100-specific inhibitors is of great interest to counteract these disease states, and thus understanding how to interrupt these allosteric biomolecular interactions represents an opportunity to address such diseases therapeutically.